OncoSec Medical Incorporated (ONCS) : Traders are bullish on OncoSec Medical Incorporated (ONCS) as it has outperformed the S&P 500 by a wide margin of 3.58% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.67%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.6% in the last 1 week, and is up 7.06% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.98% and the 50-Day Moving Average is 7.47%. OncoSec Medical Incorporated has dropped 7.14% during the last 3-month period . Year-to-Date the stock performance stands at -23.21%.
OncoSec Medical Incorporated (NASDAQ:ONCS): stock turned positive on Friday. Though the stock opened at $1.78, the bulls momentum made the stock top out at $1.95 level for the day. The stock recorded a low of $1.72 and closed the trading day at $1.82, in the green by 1.68%. The total traded volume for the day was 981,971. The stock had closed at $1.79 in the previous days trading.
OncoSec Medical Incorporated is a biotechnology company focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The Companys portfolio includes biologic immunology therapeutic product candidates intended to treat a range of tumor types. The Companys technology includes property relating to its ImmunoPulse delivery technology. The Companys ImmunoPulse is an electroporation delivery device that the Company uses in combination with its therapeutic product candidates, including deoxyribonucleic acid (DNA) plasmids that encode for immunologically active agents, to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. Its electroporation devices consist of an electrical pulse generator and disposable applicators. The Companys ImmunoPulse product candidates are based on its DNA based immunotherapy technology.